Follow the Definium Therapeutics, Inc. share price and the full directors' dealings record of the company, a listed issuer based in United States. Shares are listed on US US, under the oversight of SEC (Form 4). The latest transaction was filed on 26 June 2026 (Cession). Among the most active insiders: Barrow Robert. Every trade is accessible without an account.
16
Insider Decl.
0
Thresholds
·
0 ops.
Buy Volume
·
5 ops.
Sell Volume
25Σ signal
Informational score on this market. Our backtest validates the signal only on 8 EU venues; elsewhere (notably US markets) insider buys historically invert or do not hold. Not a recommendation.
Σ
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI-generated analysis. Opinion, not investment advice. Not backtested. Built from public filings and financials. No price target, no buy or sell recommendation.
Definium Therapeutics, Inc. is a company focused on developing innovative therapies for the treatment of serious diseases. It is listed on the XNAS market.